Capecitabine maintenance therapy following docetaxel/capecitabine combination treatment in patients with metastatic breast cancer

  • Authors:
    • Zeki Gokhan Surmeli
    • Umut Varol
    • Burcu Cakar
    • Mustafa Degirmenci
    • Cagatay Arslan
    • Gonul Demir Piskin
    • Baha Zengel
    • Burcak Karaca
    • Ulus Ali Sanli
    • Ruchan Uslu
  • View Affiliations

  • Published online on: July 29, 2015     https://doi.org/10.3892/ol.2015.3546
  • Pages: 2598-2602
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to analyze the efficacy of maintenance therapy with single agent capecitabine for human epidermal growth factor receptor (HER2) negative metastatic breast cancer (MBC) patients following disease control with 6 cycles of docetaxel plus capecitabine chemotherapy as the first‑line treatment. As an initial treatment, 6 cycles of docetaxel plus capecitabine followed by maintenance therapy with capecitabine were administered. A total of 55 patients received combination therapy and 48 patients proceeded to maintenance therapy: Of these, 32 patients (66.7%) were postmenopausal and 37 (77.1%) had estrogen and progesterone receptor positive disease. The median progression‑free survival rate with maintenance therapy was 5.5 months (95% CI, 0‑11.4 months) and the median overall survival (OS) was 26.6 months (95% CI, 21.8‑30.1 months). The use of maintenance therapy improved previous responses in 4 patients (8.3%; 2 partial and 2 complete responses) and 32 patients (66.7%) had stable disease. The median number of maintenance therapy cycles applied was 6.5 (range 1‑28, total 441). The observation of side effects, including grade 3/4 neutropenia, febrile neutropenia and fatigue was more common during combination therapy. The results of the present study indicate that maintenance with single agent capecitabine therapy is an effective and tolerable treatment option for HER2 negative MBC patients in which disease control with 6 cycles of docetaxel plus capecitabine chemotherapy is achieved in the first-line setting.
View Figures
View References

Related Articles

Journal Cover

October-2015
Volume 10 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Surmeli ZG, Varol U, Cakar B, Degirmenci M, Arslan C, Piskin GD, Zengel B, Karaca B, Sanli UA, Uslu R, Uslu R, et al: Capecitabine maintenance therapy following docetaxel/capecitabine combination treatment in patients with metastatic breast cancer. Oncol Lett 10: 2598-2602, 2015.
APA
Surmeli, Z.G., Varol, U., Cakar, B., Degirmenci, M., Arslan, C., Piskin, G.D. ... Uslu, R. (2015). Capecitabine maintenance therapy following docetaxel/capecitabine combination treatment in patients with metastatic breast cancer. Oncology Letters, 10, 2598-2602. https://doi.org/10.3892/ol.2015.3546
MLA
Surmeli, Z. G., Varol, U., Cakar, B., Degirmenci, M., Arslan, C., Piskin, G. D., Zengel, B., Karaca, B., Sanli, U. A., Uslu, R."Capecitabine maintenance therapy following docetaxel/capecitabine combination treatment in patients with metastatic breast cancer". Oncology Letters 10.4 (2015): 2598-2602.
Chicago
Surmeli, Z. G., Varol, U., Cakar, B., Degirmenci, M., Arslan, C., Piskin, G. D., Zengel, B., Karaca, B., Sanli, U. A., Uslu, R."Capecitabine maintenance therapy following docetaxel/capecitabine combination treatment in patients with metastatic breast cancer". Oncology Letters 10, no. 4 (2015): 2598-2602. https://doi.org/10.3892/ol.2015.3546